Antineo

Antineo joined Antineo in April 2024 as Chief Executive Officer.

Graduated from EM Lyon Business School (International MBA 2010), Renaud Marin-Sidgwick has extensive experience in the Biotech/Medtech domain as an entrepreneur, executive and mentor in France and the UK.

He is bringing to Antineo his expertise in helping companies successfully embrace new strategic challenges and opportunities and nurture an innovation culture in order to remain competitive.

Marie joined Antineo in June 2022 as Study Director and Head of Business Development.

She is in charge of establishing the study designs with the clients, of transmitting the client's requests and needs to the operational team, and redacting the Study Reports.

Marie obtained her PhD in Pharmacology at the University of Lille, for her work on characterizing and evaluating the efficacy of small anti-Alzheimer molecules in mouse models. During her PhD, she acquired a solid experience in experimentation on rodents and small molecules, and she validated her Level I for Animal Experimentation.

Doriane joined the CRCL team Anticancer Antibodies, directed by Pr Charles Dumontet in 2010 as Assistant Engineer, and she has joined Antineo in 2015 and is one of the founding employees of Antineo.

She is in charge of the planification and realization of the experiments for our clients, as well as for Antineo's internal R&D projects. She is the referent for in vitro experimentations and for liposomal formulations.

Doriane began her studies at the Catholic University of Lyon (ESTBB) where she obtained her diploma in 2010 as a technician in Biochemistry and Biology. During this three-year training, she performed a one-year internship in a private company developing antibodies. She completed her training by a Level II for Animal Experimentation as well as in surgical procedures.

Pierre-Antoine joined Antineo in June 2018 as Study Assistant, and he was promoted to the position of Junior Study Manager in April 2019.

He is in charge of the planification and realization of the experiments for our clients, as well as for Antineo's internal R&D projects.

Pierre-Antoine obtained his diploma of Brevet de Technicien Supérieur in 2016 at the University of Clermont-Ferrand, with a specialization in Biotechnologies. He then completed his training by a professionalizing course in Molecular and Cellular Studies for bioactive molecules at the University of Clermont-Ferrand.

During this straining, Pierre-Antoine acquired a solid experience in experimentation on rodents and obtained his Level II authorization as well as in surgical procedures.

Prior to joining the company, Pierre-Antoine was Assistant Engineer for sero-immunology analysis on cattle.

Marine joined Antineo in January 2023 as Study Manager.

She is in charge of the planification and realization of the experiments for our clients, as well as for Antineo's internal R&D projects.

Marine is graduated of a Master's degree in Drug Sciences with a specialization of Pharmacology. She also obtained his Level II for Animal Experimentation as well as in surgical procedures in 2018.

After 6 months of Master's degree internship at Antineo, Aurélie came back in the team on September 2023 for 3 years as PhD student.

Her project is the development of in vitro systems for cancer therapies evaluation like 3D bioprinted models.

After studying pharmacy, she completed a Master's degree in therapeutic innovations in oncology (ITC), and she validated her Level I for Animal Experimentation.

Flore joined Antineo in September 2024 as Study Assistant in apprenticeship.

She is currently in the 3rd year of Biological Engineering program. She will be mainly in charge of the technical management of experimental protocols and animal monitoring.

Since February 2025, Jean-Philippe joined the Antineo team as an Administrative Manager.

For over 13 years, he worked in the hotel industry, where he was trained in marketing, management and administration, before becoming Executive assistant in 2021.

On the strength of these experiences, he decided in 2022 to leave the hotel industry to open up to new perspectives and took advantage of his cross-disciplinary skills to join an architectural firm as an Administrative manager for 2 years.

Charles is an M.D. Ph.D. with specializations in internal medicine, oncology and haematology. After a 2 year post-doctoral fellowship in Stanford Medical School he created his research team and is now Principal Investigator. of the Anticancer Antibody team at the CRCL, Lyon.

He has performed animal experimentation for over 20 years and conducted a variety of translational research projects as well as drug development trials in haematology and solid tumours.

He also teaches haematology for medical students and coordinates a master's program in cancer research at the University Claude Bernard Lyon 1.

He is deputy director of the Cancer Research Centre of Lyon, of the translational research programme LYRIC (coordinator Pr Jean Yves Blay) and of the Fédération Hospitalo-Universitaire DIPOHL (Pr Gilles Salles, HCL). He is the chair of the Hospices Civils de Lyon Research Council.

Thanks to his clinical and preclinical expertise, Charles advises Antineo customers for their preclinical and clinical development program.

Pr Blay is an oncologist, as well as a researcher and teacher at the Lyon Medicine Faculty. He is a worldwide renown specialist for sarcoma treatment, and was previously President of the European Organisation for Research and Treatment of Cancer (EORTC).

He is currently the Director of the anticancer center Centre Léon Bérard (CLB) in Lyon and a P.I. in the Cancer Research Center of Lyon (CRCL).
His expertise on sarcomas and oncology is an important asset for Antineo.

Pr Ray-Coquard is an oncologist at the Medical Oncology Department of the Institute of Clinical Sciences (Centre Léon Bérard, Lyon). She is a specialist in rare ovarian cancers and is leading clinical trials on patients suffering from such cancers, as well other more frequent gynaecological cancers. Pr Ray-Coquart is also the coordinator of a National Network for rare Ovarian cancers, as well as the National Observatory on such pathologies. Antineo benefits from her expertise on ovarian tumours, sarcomas and gynaecological cancers.

Dr Tredan is an oncologist at the Centre Léon Bérard. His domains of expertise are on gynaecologic cancers, as well as ovarian and breast tumours. He is involved in several translational and drug development programmes.

Dr Jordheim is a PharmD/PhD, associate professor at the School of Pharmacy and member of the Oncopharmacology team of Cancer Research Center of Lyon (CRCL). He has performed research on preclinical onco-pharmacology with a particular interest in drug resistance as well as on nucleotide metabolism in cancer cell biology. Dr Jordheim brings his expertise in pharmacology, formulation and cell-based experiments to Antineo.